Article info

Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study

Authors

  1. Correspondence to Professor Johann de Bono; Johann.de-Bono{at}icr.ac.uk
View Full Text

Citation

Zucali PA, Lin C, Carthon BC, et al
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study

Publication history

  • Accepted December 7, 2021
  • First published January 20, 2022.
Online issue publication 
January 20, 2022
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.